These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 27853282)

  • 21. Design, synthesis, and biological evaluation of novel pan agonists of FFA1, PPARγ and PPARδ.
    Li Z; Zhou Z; Deng F; Li Y; Zhang D; Zhang L
    Eur J Med Chem; 2018 Nov; 159():267-276. PubMed ID: 30296685
    [TBL] [Abstract][Full Text] [Related]  

  • 22. KDT501, a derivative from hops, normalizes glucose metabolism and body weight in rodent models of diabetes.
    Konda VR; Desai A; Darland G; Grayson N; Bland JS
    PLoS One; 2014; 9(1):e87848. PubMed ID: 24498211
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-diabetic effects of emodin involved in the activation of PPARgamma on high-fat diet-fed and low dose of streptozotocin-induced diabetic mice.
    Xue J; Ding W; Liu Y
    Fitoterapia; 2010 Apr; 81(3):173-7. PubMed ID: 19699280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
    Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Upregulation of PPARγ by Aegle marmelos ameliorates insulin resistance and β-cell dysfunction in high fat diet fed-streptozotocin induced type 2 diabetic rats.
    Sharma AK; Bharti S; Goyal S; Arora S; Nepal S; Kishore K; Joshi S; Kumari S; Arya DS
    Phytother Res; 2011 Oct; 25(10):1457-65. PubMed ID: 21351301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Toona Sinensis ameliorates insulin resistance via AMPK and PPARγ pathways.
    Liu HW; Huang WC; Yu WJ; Chang SJ
    Food Funct; 2015 Jun; 6(6):1855-64. PubMed ID: 25940430
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DPP-4 inhibitor and PPARγ agonist restore the loss of CA1 dendritic spines in obese insulin-resistant rats.
    Sripetchwandee J; Pipatpiboon N; Pratchayasakul W; Chattipakorn N; Chattipakorn SC
    Arch Med Res; 2014 Oct; 45(7):547-52. PubMed ID: 25281415
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A step ahead of PPARγ full agonists to PPARγ partial agonists: therapeutic perspectives in the management of diabetic insulin resistance.
    Chigurupati S; Dhanaraj SA; Balakumar P
    Eur J Pharmacol; 2015 May; 755():50-7. PubMed ID: 25748601
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypoglycemic activity of 6-bromoembelin and vilangin in high-fat diet fed-streptozotocin-induced type 2 diabetic rats and molecular docking studies.
    Stalin A; Irudayaraj SS; Gandhi GR; Balakrishna K; Ignacimuthu S; Al-Dhabi NA
    Life Sci; 2016 May; 153():100-17. PubMed ID: 27091376
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, Synthesis, and Biological Evaluation of Thiazolidine-2,4-dione Conjugates as PPAR-γ Agonists.
    Nazreen S; Alam MS; Hamid H; Shahar Yar M; Dhulap A; Alam P; Pasha MA; Bano S; Alam MM; Haider S; Kharbanda C; Ali Y; Pillai K
    Arch Pharm (Weinheim); 2015 Jun; 348(6):421-32. PubMed ID: 25900064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oxadiazolyl thiazolidinedione as a non-adipogenic PPAR-γ partial agonist and its effect on glucose homeostasis in type 2 diabetes.
    Thangavel N; Bratty MA; Javed SA; Ahsan W; Hazmi HA
    J Biol Regul Homeost Agents; 2019; 33(3):707-719. PubMed ID: 31204468
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FK-614, a selective peroxisome proliferator-activated receptor gamma agonist, improves peripheral glucose utilization while decreasing hepatic insulin extraction in alloxan-induced diabetic dogs.
    Uchino H; Kim T; Lam TK; Yoshii H; Klement P; Williams W; Kawamori R; Giacca A
    Metabolism; 2005 Sep; 54(9):1250-8. PubMed ID: 16125538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
    Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
    Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum endotrophin identifies optimal responders to PPARγ agonists in type 2 diabetes.
    Karsdal MA; Henriksen K; Genovese F; Leeming DJ; Nielsen MJ; Riis BJ; Christiansen C; Byrjalsen I; Schuppan D
    Diabetologia; 2017 Jan; 60(1):50-59. PubMed ID: 27631136
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro.
    Burgermeister E; Schnoebelen A; Flament A; Benz J; Stihle M; Gsell B; Rufer A; Ruf A; Kuhn B; Märki HP; Mizrahi J; Sebokova E; Niesor E; Meyer M
    Mol Endocrinol; 2006 Apr; 20(4):809-30. PubMed ID: 16373399
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PAM-1616, a selective peroxisome proliferator-activated receptor γ modulator with preserved anti-diabetic efficacy and reduced adverse effects.
    Kim MK; Chae YN; Choi SH; Moon HS; Son MH; Bae MH; Choi HH; Hur Y; Kim E; Park YH; Park CS; Kim JG; Lim JI; Shin CY
    Eur J Pharmacol; 2011 Jan; 650(2-3):673-81. PubMed ID: 20974124
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peroxisome proliferator-activated receptor (PPAR)-alpha agonism prevents the onset of type 2 diabetes in Zucker diabetic fatty rats: A comparison with PPAR gamma agonism.
    Bergeron R; Yao J; Woods JW; Zycband EI; Liu C; Li Z; Adams A; Berger JP; Zhang BB; Moller DE; Doebber TW
    Endocrinology; 2006 Sep; 147(9):4252-62. PubMed ID: 16728496
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel transcriptome profiling analyses demonstrate that selective peroxisome proliferator-activated receptor γ (PPARγ) modulators display attenuated and selective gene regulatory activity in comparison with PPARγ full agonists.
    Tan Y; Muise ES; Dai H; Raubertas R; Wong KK; Thompson GM; Wood HB; Meinke PT; Lum PY; Thompson JR; Berger JP
    Mol Pharmacol; 2012 Jul; 82(1):68-79. PubMed ID: 22496518
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Docking, synthesis and anti-diabetic activity of novel sulfonylhydrazone derivatives designed as PPAR-gamma agonists.
    Zapata-Sudo G; Lima LM; Pereira SL; Trachez MM; da Costa FP; Souza BJ; Monteiro CE; Romeiro NC; D'Andrea ÉD; Sudo RT; Barreiro EJ
    Curr Top Med Chem; 2012; 12(19):2037-48. PubMed ID: 23167793
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis, and biological evaluation of novel sulindac derivatives as partial agonists of PPARγ with potential anti-diabetic efficacy.
    Huang F; Zeng Z; Zhang W; Yan Z; Chen J; Yu L; Yang Q; Li Y; Yu H; Chen J; Wu C; Zhang XK; Su Y; Zhou H
    Eur J Med Chem; 2021 Oct; 222():113542. PubMed ID: 34118723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.